TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and…